Johnson & Johnson vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Johnson & Johnson trades at $248.49 (market cap $598.96B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.79. The key difference: Johnson & Johnson pays a 2.15% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| JNJ | VWO | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $61.24 |
52-Week Low | $164.36 | $49.54 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VWO trades at $57.93, up 0.16% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF's low expense ratio of 0.06% and 2.4% dividend yield (The Motley Fool, 2026-06-29) appeal to cost-conscious investors. Recent news highlights strong capital inflows into emerging markets and comparisons with peers like EEM, emphasizing VWO's cost advantage and exposure to developing economies without heavy China reliance.
Outlook: VWO offers diversified emerging market access at low cost, but faces risks from geopolitical tensions and China's economic volatility. Investor sentiment is mixed, with technicals suggesting caution despite fundamental strengths in expense efficiency and yield.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →